Anti-fibrotic therapeutic - AdaptVac
Latest Information Update: 11 Feb 2024
At a glance
- Originator AdaptVac
- Class Antifibrotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Fibrosis
Most Recent Events
- 20 Oct 2023 Preclinical trials in Fibrosis in Denmark (Parenteral), before October 2023 (AdaptVac pipeline, October 2023)